Since early studies demonstrated the feasibility of hematopoietic reconstitution by infusion of peripheral blood stem cells (PBSC), 1-4 autologous PBSC transplantation has We infused peripheral blood stem cells (PBSC) into 51 patients with various malignant disorders, after myebecome an established procedure in clinical oncology. In many centers, including our own, the majority of autololoablative conditioning. Twenty-four patients also received autologous bone marrow (PBSC + BM). In a gous transplantation procedures now employ stem cells harvested from peripheral blood rather than bone marrow. multivariate analysis, the only statistically significant predictors of neutrophil engraftment were log-dose PBSC transplantation offers several advantages over autologous bone marrow transplantation. PBSC collection by CFU-GM (P Ͻ 0.001) and the number of prior chemotherapy regimens (P = 0.004). The factors predicting apheresis involves less trauma to the patient than bone marrow aspiration and enables autologous hematopoietic RBC and platelet engraftment were log-dose CFU-GM (P = 0.002), PBSC + BM infusion (P = 0.007) and the reconstitution in cases in which metastasis, fibrosis or postradiation acellularity precludes marrow harvesting. Moreabsence of neoplastic bone marrow involvement (P = 0.009). Seven patients remained platelet and/or red cell over, there is evidence that PBSC engraft more rapidly than autologous marrow stem cells, 5-9 with the potential benefits transfusion-dependent for 100 days or more post-transplant after good neutrophil recovery. Six of these seven of reduced post-transplantation morbidity and a shorter hospital stay. long-term engraftment failures, as well as five additional patients, received Ͻ10 5 CFU-GM/kg. Of the 11 patients PBSC transplantation is not, however, without disadvantages. Under physiological conditions, peripheral blood who received Ͻ10 5 CFU-GM/kg (low-dose patients), seven were PBSC recipients, of whom six were longcontains far fewer stem cells than bone marrow. 10,11 Chemotherapeutic agents [12][13][14][15][16] and/or hematopoietic growth facterm engraftment failures. In contrast, there were no long-term engraftment failures among the four low-dose tors 5-9 may be used to mobilize stem cells from the marrow into the peripheral blood, but there is significant morbidity autologous marrow recipients. This difference in longterm engraftment failure rate was significant (P = associated with the use of these agents. Even with stem cell mobilization, multiple apheresis and cryopreservation 0.015). The low-dose PBSC patients all had a diagnosis of lymphoma with bone marrow involvement. The lowprocedures are required in the majority of cases to obtain adequate numbers of stem cells for hematopoietic reconstidose PBSC + BM group was more heterogeneous, but no patient had malignant involvement of the marrow.
levels remain poorly defined, as do the differences in dosaration of light density cells using a COBE 2991 cell processor (COBE BCT). All products were frozen in TC-199, age requirements between patients receiving peripheral blood and marrow-derived products. We have recently containing final concentrations of 40% autologous plasma and 10% DMSO, using a controlled-rate freezer (Cryomed, reviewed our PBSC engraftment data for patients undergoing marrow-ablative conditioning regimens and will present New Baltimore, MD, USA), prior to storage at −196°C in liquid nitrogen. 23 them, comparing patients who received PBSC alone with those who received bone marrow stem cells in addition to PBSC.
Transplantation procedures
Breast cancer patients were conditioned with a regimen Patients and methods consisting of cyclophosphamide, 6 g/m 2 , carboplatin, 800 mg/m 2 and thiotepa, 500 mg/m 2 . Ovarian cancer patients Patients received carboplatin, 1600 mg/m 2 , VP-16, 800 mg/m 2 , thiotepa, 500-800 mg/m 2 and mitoxantrone, 36-48 mg/m 2 . Of We infused PBSC into 51 patients with a variety of hematothe remaining 34 patients, 29 were conditioned with cyclological and non-hematological malignancies, after myelophosphamide, 6 g/m 2 , VP-16, 1800 mg/m 2 , carboplatin, ablative conditioning. Our standard procedure was to infuse 1000 mg/m 2 and 8-13 Gy TBI, on a phase I study. Five both PBSC and autologous bone marrow in all cases except lymphoma patients who had received dose-limiting radithose in which preliminary evaluation revealed malignant ation therapy prior to transplantation were conditioned with involvement of the bone marrow. Thus, 24 patients cyclophosphamide, 120 mg/kg, VP-16, 60 mg/kg and received PBSC along with autologous bone marrow (PBSC BCNU, 15 mg/kg. Stem cell products were thawed in a + BM), while 27 patients received PBSC alone. Demo-37°C water bath before infusion. As soon as each bag of graphic and diagnostic data for the patient groups receiving cells was thawed, the contents were infused rapidly, over a PBSC alone or PBSC + BM are detailed in Table 1 .
5-10 min period, through a large-bore intravenous catheter. After stem cell infusion, all patients received G-CSF, 5 Stem cell harvesting procedures g/kg/day subcutaneously, until an absolute neutrophil count in excess of 10 9 /l had been maintained for 3 consecu-PBSC were mobilized by administration of G-CSF tive days. (Amgen, Thousand Oaks, CA, USA) at a dosage of 5 g/kg/day subcutaneously for 7-12 days. In some cases, this was timed to coincide with a post-chemotherapy Assay procedures rebound. PBSC collection was started on day 5 of G-CSF TNC and mononuclear cell (MNC) counts were determined administration or when the peripheral WBC exceeded using a Technicon H*2 analyzer (Miles, Tarrytown, NY, 5 × 10 9 /l after chemotherapy. Aphereses were performed USA). MNC counts were obtained from the basophil-lobudaily or on alternate days until at least 8 × 10 8 total larity channel (low side-scatter population). In the case of nucleated cells (TNC)/kg were obtained. Apheresis was bone marrow samples, cell counts were performed after performed using a COBE Spectra (COBE BCT, Lakewood, replacement of the sample plasma with saline. 24 Clonal CO, USA), processing at least 10 l per procedure. Bone assays for hematopoietic progenitor cells were performed marrow was harvested from the iliac crest under general using a commercial, premixed methyl-cellulose medium anesthesia using standard procedures.
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(MethoCult, Stem Cell Technologies, Vancouver, BC, Canada), containing erythopoietin and a source of colonyCryopreservation techniques stimulating factors (PHA-conditioned lymphocyte-conditioned medium). Triplicate cultures were set up in 24-Excess plasma was removed from the PBSC products after well plates at each of six concentrations, ranging from centrifugation for 10 min at 1200 r.p.m. Buffy coat prep-2.5 × 10 4 to 8 × 10 5 cells/ml in doubling increments and arations were obtained from bone marrow aspirates by sepwere scored on day 14. Table 2 along with engraftment data, includHodgkin's disease 3 7 ing days to neutrophils Ͼ0.5 × 10 9 /l and days to platelet Non-Hodgkin's lymphoma 14 6 and red cell transfusion independence. In the preliminary variance. 25 In the first analysis, the various factors were involvement of the bone marrow (P = 0.009). As autologous bone marrow was only infused into patients without evaluated as predictors of short-term engraftment, with the duration of post-transplant neutropenia (days to neutrophils evidence of neoplastic bone marrow involvement, there was a very high degree of correlation between the second two Ͼ0.5 × 10 9 /l) as the dependent variable. In the second analysis, the same factors were evaluated as predictors of variables. long-term engraftment, the dependent variable being the sum of the duration of red cell transfusion dependence and
Long-term engraftment failures platelet transfusion dependence.
The results of these analyses are shown in Table 3 . While Histogram analysis of our red cell and platelet engraftment data ( Figure 1 ) identified seven patients who, after early age was a marginal negative predictor of both short-term engraftment (P = 0.056) and long-term engraftment (P = and sustained neutrophil recovery, remained platelet and/or red cell transfusion-dependent for extended periods (Ͼ100 0.057), in neither case was the relationship statistically significant. Similarly, the inclusion of TBI in the conditioning days) post-transplant. These patients were clear outliers from the remainder of the population and their demoregimen was a marginal, but statistically insignificant negative predictor of long-term engraftment (P = 0.054). Of the graphic, clinical and infusion data are summarized in Table  4 (cases 1-7). The median time for this group to reach neuvariables evaluated, only the log-dose of infused CFU-GM and the number of prior chemotherapy regimens were stattrophils Ͼ0.5 × 10 9 /l was 14 days (range 10-16 days) as compared with 11 days for the patient population as a istically significant predictors of short-term engraftment (P Ͻ 0.001 and P = 0.044, respectively). These two variables whole. While their infused CFU-GM doses ranged from 2.53 × 10 4 /kg to 79.6 × 10 4 /kg (median 6.93 × 10 4 /kg), six did not show any significant intercorrelation. Three variables were found to be significant predictors of long-term of these seven patients received fewer than 10 5 CFU-GM/kg. It was noted that all the long-term engraftment failengraftment: the log-dose of infused CFU-GM (P = 0.002), the nature of the infused product (PBSC or PBSC + BM, ures occurred in patients who received PBSC only and that none occurred in the PBSC + BM group. P = 0.007) and the presence or absence of neoplastic Table 3 Multivariate analysis of variance for demographic, clinical and graft-related factors as predictors of short-term engraftment (dependent variable, days to neutrophils Ͼ0.5 × 10 9 /l) and long-term engraftment (dependent variable, total duration of red cell and platelet transfusion dependence) Table 4 ). These differences with respect to long-term engraftment failure rate were analyzed by Fisher's exact test, 26 and were found to be significant (P = 0.015).
On clinical review (see Table 4 ), it was noted that all seven low-dose PBSC recipients had a diagnosis of lymphoma with bone marrow involvement, classified as nonHodgkin's lymphoma in six. The low-dose PBSC + BM group included two cases of Hodgkin's disease, one of breast cancer and one of granulocytic sarcoma involving the breast, none with bone marrow involvement. The lowdose PBSC group had received a mean of 2.8 prior chemotherapy regimens, as compared with 1.5 for the low-dose PBSC + BM group, and an unpaired t-test 27 indicated that the difference was significant (0.01 Ͼ P Ͼ 0.001). It was further noted that all seven low-dose PBSC patients patients. This difference was also found to be significant 100 days.
(P = 0.024) using Fisher's exact test.
26 Differences between the low-dose groups with respect to prior radiation therapy and the regimens used for PBSC mobilization were insigEngraftment data for patients receiving Ͻ10 
CFU-GM/kg
As the results of our study raised the possibility of longDiscussion term repopulating defects in the PBSC products infused into some of our patients, we undertook a more detailed data analysis for the subset of patients who received fewer
The only significant predictors of neutrophil engraftment in our study were the log-dose of infused CFU-GM (P Ͻ than 10 5 CFU-GM/kg (low-dose patients). A review of our database identified another five low-dose patients (cases 8-0.001) and the number of prior chemotherapy regimens (P = 0.044). While a correlation between infused CFU-GM 12 in Table 4 ), in addition to the long-term engraftment failure patients identified above. These additional low-dose numbers and days to neutrophil engraftment has been demonstrated in a majority of studies of bone marrow recipicases included one PBSC recipient, three PBSC + BM recipients and a patient who received an autologous bone ents, 28-31 data for PBSC recipients are less conclusive, some studies showing significant correlation, 32 others showing marrow transplant without PBSC supplementation. Among the seven low-dose PBSC recipients (cases 2-8 in Table  none . 33 It was of interest to note that the effect of the number of prior chemotherapy regimens on neutrophil 4), there were six long-term engraftment failures, as defined Table 4 Demographic, clinical and infusion data for patients who received Ͻ10 5 CFU-GM/kg and/or remained transfusion dependent for more than 100 days post-transplant /l. HD = Hodgkin's disease, NHL = non-Hodgkin's lymphoma; Gr Sarc = granulocytic sarcoma; Ca Br = breast cancer. engraftment was independent of the log-dose of infused that mobilized PBSC populations contained higher proportions of primitive hematopoietic progenitor cells than CFU-GM, suggesting that the relationship was not a reflection of impaired stem cell mobilization. An alternative bone marrow. However, the PBSC products evaluated by Pettengell et al, 20 were derived exclusively from patients hypothesis is that delayed neutrophil engraftment resulted from chemotherapy-induced damage to the hematopoietic without evidence of bone marrow metastasis or other hematological disease, who had received no more than one premicroenvironment.
The log-dose of infused CFU-GM was also the major vious chemotherapy regimen and no prior radiation therapy. The apparent long-term repopulating defect observed in predictor of long-term hematopoietic reconstitution in our study, as indicated by red cell and platelet transfusion indeour study was relative rather than absolute. Our long-term engraftment failures were confined to a group of heavily pendence. In contrast to neutrophil recovery, long-term hematopoietic reconstitution is a function of primitive, nonpre-treated lymphoma patients with metastatic involvement of the bone marrow. Our study population included 10 clonogenic stem cells and has generally been shown to correlate poorly with infused clonogenic cell numbers. Assay additional lymphoma patients (two Hodgkin's disease, eight non-Hodgkin's lymphoma) who received PBSC procedures exist whereby primitive stem cells may be identified and quantitated 34 and there is evidence that the alone, without bone marrow back-up. On clinical review, the only significant difference between this group of results of such assays correlate with various parameters of long-term engraftment. 35 However, these assays take sevpatients and the long-term engraftment failure group was that they received Ͼ10 5 CFU-GM/kg (median 5.7 × 10 5 , eral weeks to complete, are labor-intensive and are not sufficiently reliable to justify their use in the clinical setting. range 1.08-76.6 × 10 5 ). All these patients engrafted successfully, indicating that any qualitative defect in their For practical purposes, autologous stem cell infusion products that are adequate in terms of clonogenic cell numbers respective PBSC products could be overcome by infusion of a larger number of cells. are assumed also to be adequate in terms of long-term repopulating capacity, an assumption supported by the results
There is thus little, if any evidence, to support the existence of a general long-term repopulating defect in PBSC of our study.
Patients undergoing PBSC transplantation in our study as compared with bone marrow. It is far more likely that the differences in outcome between low-dose bone marrow were at high risk for long-term engraftment failure if they received Ͻ10
5 CFU-GM/kg. However, it is generally and PBSC recipients in our study resulted from factors specific to our own patient population. The diagnosis of lymimpractical to delay transplantation until CFU-GM counts are available, as clonal assays take up to 2 weeks to comphoma, carried by all seven low-dose PBSC/engraftment failure patients in our series, is one potential factor. While plete. Our experience thus highlights the need for sensitive indicators of graft adequacy, for which relevant data can studies comparing PBSC transplantation to autologous bone marrow transplantation in lymphoma patients show no be generated in a reasonable period of time. TNC and MNC counts are clearly inadequate. Flow cytometric enumeration overall differences in long-term outcome, 40,41 several reports published suggest that the results of PBSC transof CD34
+ cells is the most useful method currently available for pre-transplant graft evaluation, 36 although substanplantation in such cases may be suboptimal. 33, [42] [43] [44] In studies of PBSC mobilization in lymphoma patients, Dreyfus tial technical variability has been demonstrated. 36, 37 There has also been considerable controversy with regard to the et al 33 and Craig et al 42 reported failure to obtain adequate CFU-GM doses in 21% and 24% of cases, respectively. relationship between CD34
+ counts and clonal assay data. 38, 39 We have generally observed good correlation Comenzo et al, 43 comparing PBSC engraftment in seven lymphoma patients with 18 autologous bone marrow recipibetween CFU-GM and CD34
+ counts in our PBSC and bone marrow products and have found these data more or ents, found that the period of platelet transfusion dependence was significantly longer in PBSC recipients (33 days) less equally predictive of neutrophil engraftment (SA Bentley et al, unpublished data). CD34
+ data were unavailthan in marrow recipients (16 days). In the series reported by Dreyfus et al 33 and by Pierelli et al, 44 the number able for several of the patients reported in the present study and could not, therefore, be included in our multivariate of patients remaining thrombocytopenic (platelets Ͻ50 × 10 9 /l) for more than 6 months after transplantation analyses.
While long-term engraftment failure occurred in the were 24% and 13%, respectively. While suboptimal results have been reported in premajority of our low-dose PBSC recipients, this complication was not observed in low-dose patients transplanted vious studies of PBSC transplantation in lymphoma patients, 33, [42] [43] [44] the biological basis for these observations with autologous bone marrow stem cells, either alone or in combination with PBSC. This difference between the PBSC remains undefined. On reviewing the seven low-dose PBSC/engraftment failure patients in our series, and comand PBSC + BM patient groups raises the possibility of differences in long-term repopulating capacity between bone paring them with the low-dose PBSC + BM group, some common features become evident. Metastatic lymphoma, marrow and PBSC populations. Primitive hematopoietic progenitor cells in bone marrow and PBSC populations detected in the bone marrow of all seven low-dose PBSC recipients, was the specific factor precluding bone marrow have been enumerated in a number of recent studies [17] [18] [19] [20] 35 and no consistent differences have been reported. In the stem cell infusion in these patients. In contrast, the lowdose PBSC + BM group did not include any non-Hodgkin's study of Pettengell et al 20 primitive hematopoietic progenitors in bone marrow, cord blood and G-CSF-mobilized lymphoma cases, nor did any of these patients show evidence of bone marrow metastasis. The low-dose PBSC PBSC products were quantitated as long-term culture initiating cells using a limiting dilution assay. 34 It was found patients had also received significantly more prior chemo- 
